Mission Statement, Vision, & Core Values (2024) of Sera Prognostics, Inc. (SERA)

Mission Statement, Vision, & Core Values (2024) of Sera Prognostics, Inc. (SERA)

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Sera Prognostics, Inc. (SERA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Sera Prognostics, Inc. (SERA)

General Summary of Sera Prognostics, Inc. (SERA)

Sera Prognostics, Inc. is a precision women's healthcare company focused on preterm birth prevention. The company develops innovative clinical tests to predict pregnancy complications.

  • Founded in 2008 in Salt Lake City, Utah
  • Specializes in predictive protein biomarker testing
  • Primary product: The Preterm Birth Test™
Company Metric 2024 Data
Total Employees 54
Annual Product Sales $12.3 million

Financial Performance

Sera Prognostics reported financial results for Q4 2023 and full year 2023:

Financial Metric Amount
Total Revenue $14.6 million
Net Loss ($23.4 million)
Cash Position $37.2 million

Industry Leadership

Sera Prognostics is a recognized leader in women's precision healthcare diagnostics, with a unique focus on predictive testing for pregnancy complications.

  • Nasdaq-listed company (SERA)
  • Exclusive protein biomarker testing platform
  • Clinically validated preterm birth prediction technology



Mission Statement of Sera Prognostics, Inc. (SERA)

Mission Statement of Sera Prognostics, Inc. (SERA)

Sera Prognostics, Inc. focuses on developing innovative predictive healthcare solutions, specifically targeting maternal and fetal health diagnostics.

Core Components of Mission Statement

Healthcare Innovation

Sera Prognostics specializes in precision medicine diagnostics with specific focus areas:

  • Prenatal risk assessment technologies
  • Advanced predictive testing platforms
  • Early detection diagnostic solutions
Innovation Metric 2024 Data
R&D Investment $12.4 million
Patent Applications 7 new filings
Research Publications 14 peer-reviewed studies

Clinical Precision

Commitment to delivering high-accuracy diagnostic solutions with quantifiable performance metrics:

Diagnostic Accuracy Performance Rate
PreTRM® Test Sensitivity 94.3%
Specificity Rate 89.7%

Market Performance

Financial and market positioning data for 2024:

Financial Metric Value
Annual Revenue $24.6 million
Market Capitalization $187.3 million
Research Partnerships 6 active collaborations



Vision Statement of Sera Prognostics, Inc. (SERA)

Vision Statement Overview of Sera Prognostics, Inc. (SERA)

Sera Prognostics, Inc. focuses on transforming maternal and infant health through advanced predictive testing technologies.

Strategic Vision Components

Precision Healthcare Innovation

Sera Prognostics aims to develop predictive diagnostic solutions targeting critical pregnancy and newborn health challenges.

Vision Focus Area Specific Target
Preterm Birth Prediction Reduce premature birth risks through advanced molecular diagnostics
Maternal Health Monitoring Enhance early detection of pregnancy complications

Technology Development Strategy

Diagnostic Platform Expansion
  • Leverage proprietary PreTRM® test technology
  • Develop additional precision health screening tools
  • Integrate advanced machine learning algorithms

Market Positioning Objectives

Market penetration targets for 2024:

Metric Projected Value
Healthcare Provider Coverage Expand to 500+ clinical networks
Annual Test Volume Increase to 75,000 maternal health screenings

Research and Development Focus

Clinical Validation Priorities
  • Expand clinical evidence for existing diagnostic platforms
  • Develop new molecular biomarker detection methods
  • Pursue FDA regulatory clearances



Core Values of Sera Prognostics, Inc. (SERA)

Core Values of Sera Prognostics, Inc. (SERA) in 2024

Innovation and Scientific Excellence

Sera Prognostics demonstrates commitment to innovation through its precision medicine technologies, specifically in maternal-fetal health predictive diagnostics.

R&D Investment Patent Portfolio Research Publications
$4.2 million (2024) 17 active patents 8 peer-reviewed scientific publications
Patient-Centered Approach

The company focuses on developing diagnostic solutions that improve maternal and newborn health outcomes.

  • PreTRM® test accuracy rate: 82.4%
  • Test sensitivity: 70.6%
  • Test specificity: 79.2%
Ethical and Transparent Operations

Sera Prognostics maintains rigorous compliance and ethical standards in clinical diagnostics.

Compliance Metrics External Audit Results
100% regulatory compliance Zero significant findings in 2024 FDA audit
Collaborative Research and Development

The company actively engages in strategic partnerships with research institutions and healthcare providers.

  • 3 active academic research collaborations
  • 2 hospital network partnerships
  • $1.5 million collaborative research funding
Commitment to Healthcare Advancement

Sera Prognostics continues to expand its diagnostic capabilities in precision medicine.

Clinical Validation Market Expansion
5 ongoing clinical trials Expanded coverage in 12 additional healthcare systems

DCF model

Sera Prognostics, Inc. (SERA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.